Terms: = Pancreatic cancer AND HOXD13, SPD, 3239, P35453, HOX4I
44 results:
1. Systems pharmacodynamic model of combined gemcitabine and trabectedin in pancreatic cancer cells. Part I.Çô Effects on signal transduction pathways related to tumor growth.
Miao X; Shen S; Koch G; Wang X; Li J; Shen X; Qu J; Straubinger RM; Jusko WJ
J Pharm Sci; 2024 Jan; 113(1):214-227. PubMed ID: 38498417
[TBL] [Abstract] [Full Text] [Related]
2. cancer-oocyte SAS1B protein is expressed at the cell surface of multiple solid tumors and targeted with antibody-drug conjugates.
Mandal A; Shetty J; Tran CA; Olson WC; Mandal M; Ban B; Pires ES; Adair SJ; Bauer TW; Slingluff CL; Herr JC
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38485187
[TBL] [Abstract] [Full Text] [Related]
3. Systems Pharmacodynamic Model of Combined Gemcitabine and Trabectedin in pancreatic cancer Cells. Part II: Cell Cycle, DNA Damage Response, and Apoptosis Pathways.
Miao X; Koch G; Shen S; Wang X; Li J; Shen X; Qu J; Straubinger RM; Jusko WJ
J Pharm Sci; 2024 Jan; 113(1):235-245. PubMed ID: 37918792
[TBL] [Abstract] [Full Text] [Related]
4. Differential diagnosis between pancreatic solid pseudopapillary tumors and pancreatic neuroendocrine tumors based on contrast enhanced ultrasound imaging features.
Zhang Q; Qiu YJ; Yang DH; Lu XY; Chen S; Dong Y; Wang WP
Clin Hemorheol Microcirc; 2023; 85(4):421-431. PubMed ID: 37718786
[TBL] [Abstract] [Full Text] [Related]
5. Combination of pembrolizumab and pelareorep promotes anti-tumour immunity in advanced pancreatic adenocarcinoma (PDAC).
Mahalingam D; Chen S; Xie P; Loghmani H; Heineman T; Kalyan A; Kircher S; Helenowski IB; Mi X; Maurer V; Coffey M; Mulcahy M; Benson A; Zhang B
Br J Cancer; 2023 Sep; 129(5):782-790. PubMed ID: 37443348
[TBL] [Abstract] [Full Text] [Related]
6. Predicting the survival of patients with pancreatic neuroendocrine neoplasms using deep learning: A study based on Surveillance, Epidemiology, and End Results database.
Jiang C; Wang K; Yan L; Yao H; Shi H; Lin R
Cancer Med; 2023 Jun; 12(11):12413-12424. PubMed ID: 37165971
[TBL] [Abstract] [Full Text] [Related]
7. Standard pancreatoduodenectomy versus extended pancreatoduodenectomy with modified retroperitoneal nerve resection in patients with pancreatic head cancer: a multicenter randomized controlled trial.
Lin Q; Zheng S; Yu X; Chen M; Zhou Y; Zhou Q; Hu C; Gu J; Xu Z; Wang L; Liu Y; Liu Q; Wang M; Li G; Cheng H; Zhou D; Liu G; Fu Z; Long Y; Li Y; Wang W; Qin R; Li Z; Chen R
Cancer Commun (Lond); 2023 Feb; 43(2):257-275. PubMed ID: 36579790
[TBL] [Abstract] [Full Text] [Related]
8. Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis.
Széles Á; Fazekas T; Váncsa S; Váradi M; Kovács PT; Krafft U; Grünwald V; Hadaschik B; Csizmarik A; Hegyi P; Váradi A; Nyirády P; Szarvas T
Cancer Immunol Immunother; 2023 May; 72(5):1061-1073. PubMed ID: 36385210
[TBL] [Abstract] [Full Text] [Related]
9. Immunomodulatory Role of Surfactant Protein-D in a Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) Model.
Ganguly K; Kishore U; Metkari SM; Madan T
Front Immunol; 2022; 13():930449. PubMed ID: 35874783
[TBL] [Abstract] [Full Text] [Related]
10. Non-cytomembrane PD-L1: An atypical target for cancer.
Ying H; Zhang X; Duan Y; Lao M; Xu J; Yang H; Liang T; Bai X
Pharmacol Res; 2021 Aug; 170():105741. PubMed ID: 34174446
[TBL] [Abstract] [Full Text] [Related]
11. Absence of association between pretransplant serum soluble programmed death protein-1 level and prognosis following living donor liver transplantation in patients with hepatocellular carcinoma.
Na BG; Kim YK; Hwang S; Lee KJ; Park GC; Ahn CS; Kim KH; Moon DB; Ha TY; Song GW; Jung DH; Yang H; Yoon YI; Tak E; Park YH; Lee SG
Medicine (Baltimore); 2021 Apr; 100(17):e25640. PubMed ID: 33907121
[TBL] [Abstract] [Full Text] [Related]
12. Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma.
Montemagno C; Hagege A; Borchiellini D; Thamphya B; Rastoin O; Ambrosetti D; Iovanna J; Rioux-Leclercq N; Porta C; Negrier S; Ferrero JM; Chamorey E; Pagès G; Dufies M
Oncoimmunology; 2020 Nov; 9(1):1846901. PubMed ID: 33299657
[TBL] [Abstract] [Full Text] [Related]
13. Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions.
Incorvaia L; Fanale D; Badalamenti G; Porta C; Olive D; De Luca I; Brando C; Rizzo M; Messina C; Rediti M; Russo A; Bazan V; Iovanna JL
Oncoimmunology; 2020 Oct; 9(1):1832348. PubMed ID: 33178494
[TBL] [Abstract] [Full Text] [Related]
14. Detailed Analysis of Margin Positivity and the Site of Local Recurrence After pancreaticoduodenectomy.
McIntyre CA; Zambirinis CP; Pulvirenti A; Chou JF; Gonen M; Balachandran VP; Kingham TP; D'Angelica MI; Brennan MF; Drebin JA; Jarnagin WR; Allen PJ
Ann Surg Oncol; 2021 Jan; 28(1):539-549. PubMed ID: 32451945
[TBL] [Abstract] [Full Text] [Related]
15. Total mesopancreas excision for periampullary malignancy: a single-center propensity score-matched comparison of long-term outcomes.
Quero G; Fiorillo C; Menghi R; Cina C; Galiandro F; Longo F; Sofo F; Rosa F; Tortorelli AP; Giustiniani MC; Inzani F; Alfieri S
Langenbecks Arch Surg; 2020 May; 405(3):303-312. PubMed ID: 32333095
[TBL] [Abstract] [Full Text] [Related]
16. Comparative Effectiveness of Pylorus-Preserving Versus Standard pancreaticoduodenectomy in Clinical Practice.
Calderon E; Day RW; Stucky CC; Gray RJ; Pockaj BA; Chang YH; Wasif N
Pancreas; 2020 Apr; 49(4):568-573. PubMed ID: 32282771
[TBL] [Abstract] [Full Text] [Related]
17. Prognostic value of programmed cell death ligand 1 (PD-L1) for hepatocellular carcinoma: a meta-analysis.
Li XS; Li JW; Li H; Jiang T
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32255189
[TBL] [Abstract] [Full Text] [Related]
18. Regional pancreatoduodenectomy versus standard pancreatoduodenectomy with portal vein resection for pancreatic ductal adenocarcinoma with portal vein invasion.
Oba A; Ito H; Ono Y; Sato T; Mise Y; Inoue Y; Takahashi Y; Saiura A
BJS Open; 2020 Jun; 4(3):438-448. PubMed ID: 32191395
[TBL] [Abstract] [Full Text] [Related]
19. Positive neck margin at frozen section analysis is a significant predictor of tumour recurrence and poor survival after pancreatodudenectomy for pancreatic cancer.
Crippa S; Guarneri G; Belfiori G; Partelli S; Pagnanelli M; Gasparini G; Balzano G; Lena MS; Rubini C; Doglioni C; Zamboni G; Falconi M
Eur J Surg Oncol; 2020 Aug; 46(8):1524-1531. PubMed ID: 32098733
[TBL] [Abstract] [Full Text] [Related]
20. Interstitial lung disease in advanced pancreatic ductal adenocarcinoma patients treated with gemcitabine and nab-paclitaxel combination therapy: a retrospective analysis.
Irie H; Suzuki R; Takagi T; Sugimoto M; Konno N; Sato Y; Hikichi T; Nakamura J; Hashimoto M; Ohira H
Cancer Chemother Pharmacol; 2020 Mar; 85(3):517-523. PubMed ID: 31691078
[TBL] [Abstract] [Full Text] [Related]
[Next]
